title: [Endocannabinoids: therapeutic perspectives in chronic liver diseases].
authors: INSERM, U841, France.
authors: Sophie
authors: S
authors: Lotersztajn
authors: Fatima
authors: F
authors: Teixeira-Clerc
authors: Christophe
authors: C
authors: Hezode
authors: Jeanne
authors: J
authors: Tran van Nhieu
authors: Vanessa
authors: V
authors: Deveaux
authors: Ariane
authors: A
authors: Mallat
mesh_terms: D000818:Animals; D001067:Appetite Depressants / Q000627:therapeutic use; D063385:Cannabinoid Receptor Modulators / Q000502:physiology*; D002186:Cannabinoids / Q000037:antagonists & inhibitors*; D002908:Chronic Disease; D004195:Disease Models, Animal; D018450:Disease Progression; D063388:Endocannabinoids; D005234:Fatty Liver / Q000517:prevention & control; D006019:Glycolysis / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000150:complications; D022781:Hepatocytes / Q000187:drug effects; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy; D050155:Lipogenesis / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000517:prevention & control; D008107:Liver Diseases / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors / Q000502:physiology; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors / Q000502:physiology; D000077285:Rimonabant
chemical_list: D001067:Appetite Depressants; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D063388:Endocannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D000077285:Rimonabant